Search Results for “cardiovascular” – Page 4 – media

Cardiovascular Systems, Inc. and OrbusNeich Announce FDA Clearance of the First and Only 1.0mm Coronary Balloon in the U.S.

Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the OrbusNeich® 1.0mm Sapphire® II PRO coronary balloon.
- Source: Enhancedonlinenews
- 498
- March 5, 2018
artery disease New Approvals Sapphire
New study links migraines to increased risk of cardiovascular problems

© Provided by AFPRelaxNews Migraine sufferers could be at an increased risk of certain heart problems according to new research.New international research has found that migraine sufferers may also have an increased risk of cardiovascular problems including heart attacks, stroke, blood clots, and an irregular heart rate.
- Source: msn
- 647
- February 8, 2018
cardiovascular migraine Researches
Marital Status and Outcomes in Patients With Cardiovascular Disease

Background Being unmarried is associated with decreased survival in the general population. Whether married, divorced, separated, widowed, or never‐married status affects outcomes in patients with cardiovascular disease has not been well characterized.
- Source: drugdu
- 446
- December 22, 2017
cardiovascular disease Marital Status Researches
Tudorza reduces exacerbations and demonstrates cardiovascular safety in COPD patients

AstraZeneca today announced positive top-line results of the Phase IV ASCENT trial for Tudorza Pressair (aclidinium bromide 400 μg, twice-daily), a long-acting muscarinic antagonist (LAMA), in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), with a history of cardiovascular disease and/or significant cardiovascular risk factors.
- Source: Astrazeneca
- 627
- December 8, 2017
AstraZeneca cardiovascular Clinical Trials COPD
Jardiance is the first and only oral type 2 diabetes medicine approved to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.

New data presented today showed that Jardiance® reduced the risk of cardiovascular death compared with placebo when added to standard of care in adults with type 2 diabetes and peripheral artery disease.
- Source: finance.yahoo
- 607
- November 17, 2017
cardiovascular diabetes Jardiance® peripheral artery disease
China’s Cardiovascular Drugs Import and Export Report

Cardiovascular drugs are medicines used to treat medical conditions associated with the heart or the circulatory system (blood vessels), such as arrhythmias, blood clots, coronary artery disease, high or low blood pressure, high cholesterol, heart failure, and strokes, whose therapeutic effects aim to improve cardiac functions, regulate blood flow of heart and change the circulatory system of blood distribution among other things.
- Source: Ddu
- 1,546
- October 19, 2017
cardiovascular Market Reports
FDA clears AUM’s diagnostic cardiovascular device

The US Food and Drug Administration (FDA) has cleared AUM Cardiovascular’s acoustic and electrocardiogram (ECG) device called CADence to aid detection of physiological and pathological heart murmurs.
- Source: medicaldevice-network
- 454
- August 11, 2017
CADence cardiovascular FDA heart New Approvals
Endovascular stent approved through priority green channel

Recently, the Equipment Review Center of the National Medical Products Administration released the results of the priority approval application for medical devices (No. 14 of 2024), and Shanghai Qigong Medical Technology Co., Ltd. (hereinafter referred to as Qigong Medical)’s product – endovascular stent – passed the priority approval green channel. It is worth mentioning that this product is urgently needed in clinical practice and there are no registered medical devices of the same variety in China. Qigong Medical focuses on innovative vascular intervention products Against the backdrop of an aging population, the incidence of cardiovascular diseases in China continues to rise, with high mortality rates, difficult treatment, and high risks associated with aortic disease. At present, the clinical treatment options for aortic diseases in China mainly include surgical open treatment and endovascular intervention treatment. Endovascular intervention therapy is a rapidly developing clinical treatment technique in recent years, which combines a ...
- Source: drugdu
- 30
- November 21, 2024
Novo Nordisk’s weekly weight loss formulation is officially launched

On November 17, Novo Nordisk announced that its weekly formulation of glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide (trade name: Novowin) for long-term weight management was officially launched in China, providing a weight loss option for Chinese overweight and obese patients. It is understood that with the official commercialization of Novowin, the first prescription of semaglutide for weight loss indications in public hospitals will be issued in Shanghai next week. Regarding the pricing of Novowin, Novo Nordisk responded: “We have begun to apply for Novowin provincial bidding network, and the sales price will refer to the provincial online price.” Previously, Novo Nordisk’s semaglutide for the treatment of type 2 diabetes, Novotai, has been included in the medical insurance, and the cost of a 3 ml dose is less than 800 yuan. In addition, Novowin has previously entered the private hospital channel and can be booked through the Internet platform, with a ...
- Source: drugdu
- 31
- November 21, 2024
Pumis announces equity acquisition agreement with BioNTech

According to the terms of the agreement, BioNTech will acquire 100% of Pumis’ issued share capital for a prepayment of $800 million (approximately RMB 5.781 billion) (subject to customary adjustment of the acquisition price), primarily in cash and a portion of American Depositary Shares (ADS). In addition, BioNTech will pay an additional milestone payment of up to $150 million (approximately RMB 1.084 billion) when Pumis meets the milestone conditions agreed upon by both parties. The transaction is expected to be completed in the first quarter of 2025, subject to customary delivery conditions and regulatory approvals. After the completion of this transaction, BioNTech will acquire full rights to the Pumis candidate drug pipeline and its bispecific antibody drug development platform, further expanding its business scope in China; Pumis Zhuhai will serve as the BioNTech China R&D center to conduct related R&D research; The Pumis Nantong production base, which meets international standards, ...
- Source: drugdu
- 44
- November 19, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.